Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female (sex assigned at birth, inclusive of all gender identities).
Age 18-64 years (both inclusive) at the time of signing the informed consent.
Diagnosed with type 2 diabetes mellitus greater than or equal to (\>=) 180 days before screening.
Glycated haemoglobin (HbA1c) 7.0-10.5 percent (%) (53-91 \[millimoles per mole\] mmol/mol) (both inclusive) as determined by the central laboratory at screening.
Stable daily dose \>= 90 days before screening of metformin at effective or maximum tolerated dose as judged by the investigator.
Body mass index (BMI) between 25.0 and 39.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.
Previous exposure to CagriSema in a clinical study.
You may not be if
Renal impairment with estimated Glomerular Filtration Rate (eGFR) \< 30 millilitre per minute per 1.73 square metre (mL/min/1.73 m\^2) as determined by the central laboratory at screening.
Clareo Health | A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
